Pasithea Therapeutics Announces Collaboration with The Glimpse Group
08 Mars 2022 - 2:00PM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced its partnership with The
Glimpse Group, Inc. (Nasdaq:VRAR, FSE:9DR) (“Glimpse”), a Virtual
Reality and Augmented Reality ("VR and AR") platform company and
its subsidiary company Foretell Reality. Foretell Reality applies
VR technology to various use cases of mental health therapy,
support, and human interaction.
“We are thrilled to partner with Glimpse to
bring VR and AR to patients suffering from mental health disorders.
Among its many benefits, VR unites a patient and therapist in a
shared environment, which is particularly important in situations
where the therapist is remote, such as with our at-home treatment
model. VR can also create scenarios to reflect specific traumatic
experiences or simulate emotionally loaded conversations. VR is
increasingly becoming an innovative clinical tool for patients with
specific psychiatric symptoms, which leads to improved patient
outcomes, and we look forward to co-developing the program
alongside Glimpse,” stated Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics.
Together with Glimpse, Pasithea will co-develop
VR environments to support the treatment of patients with
psychiatric disorders in a safe and effective manner.
Lyron Bentovim, President and CEO of Glimpse
commented, “VR technology is becoming widely adopted in the
healthcare industry, with a range of applications including mental
health and psychological therapies, pain management, and robotic
surgery. Glimpse, through its base of subsidiary companies, has
direct experience in developing such solutions with leading
companies, hospitals, and universities in the segment. We look
forward to our collaboration with Pasithea.”
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
About The Glimpse Group,
Inc.
The Glimpse Group (Nasdaq: VRAR, FSE:9DR) is a
Virtual and Augmented Reality platform company, comprised of
multiple VR and AR software & services companies, and designed
with the specific purpose of cultivating entrepreneurs in the VR/AR
industry. Glimpse's unique business model simplifies challenges
faced by VR/AR entrepreneurs and creates a robust ecosystem, while
simultaneously providing investors an opportunity to invest
directly into the emerging VR/AR industry via a diversified
platform. For more information on The Glimpse Group, please visit
www.theglimpsegroup.com.
Foretell Reality, a fully owned Glimpse Group
subsidiary, leverages the unique capabilities of VR technology to
enhance human interaction and applies it to various uses cases of
mental health therapy, support, and soft skills training. For more
information on Foretell Reality, please visit
www.foretellreality.com.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
The Glimpse Group Contact:
Maydan RothblumCFO & COOThe Glimpse Group,
Inc.917-292-2685maydan@theglimpsegroup.com
Glimpse (NASDAQ:VRAR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Glimpse (NASDAQ:VRAR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024